UA123697C2 - Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38 - Google Patents
Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38 Download PDFInfo
- Publication number
- UA123697C2 UA123697C2 UAA201706786A UAA201706786A UA123697C2 UA 123697 C2 UA123697 C2 UA 123697C2 UA A201706786 A UAA201706786 A UA A201706786A UA A201706786 A UAA201706786 A UA A201706786A UA 123697 C2 UA123697 C2 UA 123697C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- patient
- aml
- zeo
- treatment
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title claims abstract description 216
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title claims abstract description 202
- 238000011282 treatment Methods 0.000 title abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 107
- 230000035772 mutation Effects 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 120
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 76
- 241000282414 Homo sapiens Species 0.000 claims description 55
- 101150110186 pop8 gene Proteins 0.000 claims description 55
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 47
- 229960000684 cytarabine Drugs 0.000 claims description 47
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 claims description 44
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 39
- 229960004679 doxorubicin Drugs 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 37
- 101710141832 DNA (cytosine-5)-methyltransferase 3 Proteins 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 210000001185 bone marrow Anatomy 0.000 claims description 29
- 210000000349 chromosome Anatomy 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 22
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 21
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 21
- 230000005945 translocation Effects 0.000 claims description 19
- 230000006907 apoptotic process Effects 0.000 claims description 17
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 238000001959 radiotherapy Methods 0.000 claims description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 9
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 9
- 229960000908 idarubicin Drugs 0.000 claims description 9
- 230000005856 abnormality Effects 0.000 claims description 8
- 229960003603 decitabine Drugs 0.000 claims description 8
- 230000002068 genetic effect Effects 0.000 claims description 8
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 6
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 6
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 6
- 229930002330 retinoic acid Natural products 0.000 claims description 6
- 206010058314 Dysplasia Diseases 0.000 claims description 5
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 5
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 4
- 102000014914 Carrier Proteins Human genes 0.000 claims description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 4
- 102000043141 Nuclear RNA Human genes 0.000 claims description 4
- 108020003217 Nuclear RNA Proteins 0.000 claims description 4
- 102100022678 Nucleophosmin Human genes 0.000 claims description 4
- 108010025568 Nucleophosmin Proteins 0.000 claims description 4
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 4
- 108091008324 binding proteins Proteins 0.000 claims description 4
- 229960002436 cladribine Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims description 3
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims description 3
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 3
- 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 claims description 3
- 208000033775 Basophilic Acute Leukemia Diseases 0.000 claims description 3
- 206010008583 Chloroma Diseases 0.000 claims description 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims description 3
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims description 3
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 3
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims description 3
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims description 3
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 229960002756 azacitidine Drugs 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 229960001428 mercaptopurine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 201000005987 myeloid sarcoma Diseases 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- 229960003087 tioguanine Drugs 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 229960002594 arsenic trioxide Drugs 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000035800 maturation Effects 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229960002204 daratumumab Drugs 0.000 description 68
- 150000001413 amino acids Chemical group 0.000 description 35
- 235000018102 proteins Nutrition 0.000 description 31
- 210000005259 peripheral blood Anatomy 0.000 description 26
- 239000011886 peripheral blood Substances 0.000 description 26
- 206010028980 Neoplasm Diseases 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 24
- 229940059359 dacogen Drugs 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 20
- 230000005855 radiation Effects 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 20
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 17
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 17
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 16
- 239000012636 effector Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 238000001990 intravenous administration Methods 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 238000002673 radiosurgery Methods 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000032839 leukemia Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- 241000534414 Anotopterus nikparini Species 0.000 description 6
- 241000726103 Atta Species 0.000 description 6
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 101000911993 Ovis aries CD59 glycoprotein Proteins 0.000 description 5
- 108010004729 Phycoerythrin Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 150000004676 glycans Polymers 0.000 description 5
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 101100187345 Xenopus laevis noto gene Proteins 0.000 description 4
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000003995 blood forming stem cell Anatomy 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- -1 nicotinic acid adenine nucleotide phosphate Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000840540 Homo sapiens Iduronate 2-sulfatase Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 description 3
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000037244 polycythemia vera Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical compound OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 description 2
- YJSXHUXXMDAOCE-UHFFFAOYSA-N 5-hydroxy-8,8-dimethyl-6-(2-methylbutanoyl)-4-phenylpyrano[2,3-h]chromen-2-one Chemical compound C=1C(=O)OC=2C=3C=CC(C)(C)OC=3C(C(=O)C(C)CC)=C(O)C=2C=1C1=CC=CC=C1 YJSXHUXXMDAOCE-UHFFFAOYSA-N 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- BQOHYSXSASDCEA-KEOHHSTQSA-N Cyclic ADP-Ribose Chemical compound C([C@@H]1[C@H]([C@H]([C@@H](O1)N1C=2N=CN3C(C=2N=C1)=N)O)O)OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]3O1 BQOHYSXSASDCEA-KEOHHSTQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000750004 Nestor meridionalis Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229910020177 SiOF Inorganic materials 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008711 chromosomal rearrangement Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000002710 external beam radiation therapy Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UMIKTNNNENCAOK-NAJQWHGHSA-N (2r,3r,4s,5r)-5-[[[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-2-(3-carbamoylpyridin-1-ium-1-yl)-4-hydroxyoxolan-3-olate Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O2)[O-])=C1 UMIKTNNNENCAOK-NAJQWHGHSA-N 0.000 description 1
- 102100029632 28S ribosomal protein S11, mitochondrial Human genes 0.000 description 1
- ZZVWCKAYZSAUKR-UHFFFAOYSA-N 5-methyl-3-(4-methylpiperazin-1-yl)pyridazino[3,4-b][1,4]benzoxazine;dihydrochloride Chemical compound Cl.Cl.C1CN(C)CCN1C(N=N1)=CC2=C1OC1=CC=CC=C1N2C ZZVWCKAYZSAUKR-UHFFFAOYSA-N 0.000 description 1
- 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 1
- 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 1
- 108010027122 ADP-ribosyl Cyclase 1 Proteins 0.000 description 1
- 108050008264 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 208000033496 Acute myeloid leukaemia with myelodysplasia-related features Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229940086568 Alpha mannosidase I inhibitor Drugs 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 101000716806 Arabidopsis thaliana Protein SCO1 homolog 2, mitochondrial Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 238000003462 Bender reaction Methods 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 101100075830 Caenorhabditis elegans mab-5 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100453960 Drosophila melanogaster klar gene Proteins 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 102100035976 Exostosin-like 3 Human genes 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000533867 Fordia Species 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000875556 Homo sapiens Exostosin-like 3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101000920534 Lysinibacillus sphaericus Gamma-D-glutamyl-L-diamino acid endopeptidase 1 Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000202950 Psidium cattleyanum var. littorale Species 0.000 description 1
- 235000015126 Psidium littorale Nutrition 0.000 description 1
- 101150060303 SOK2 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101150003236 TUBG1 gene Proteins 0.000 description 1
- 229920001074 Tenite Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000016544 acute myeloid leukemia with multilineage dysplasia Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000045108 human EGFR Human genes 0.000 description 1
- 102000057422 human IDS Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- JLESVLCTIOAHPT-UHFFFAOYSA-N mmai Chemical compound C1=C(C)C(OC)=CC2=C1CC(N)C2 JLESVLCTIOAHPT-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1027—Interstitial radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1042—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head
- A61N5/1045—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy with spatial modulation of the radiation beam within the treatment head using a multi-leaf collimator, e.g. for intensity modulated radiation therapy or IMRT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
- A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087442P | 2014-12-04 | 2014-12-04 | |
| PCT/US2015/063371 WO2016089960A1 (en) | 2014-12-04 | 2015-12-02 | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA123697C2 true UA123697C2 (uk) | 2021-05-19 |
Family
ID=56092366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201706786A UA123697C2 (uk) | 2014-12-04 | 2015-12-02 | Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10793630B2 (OSRAM) |
| EP (1) | EP3227338A4 (OSRAM) |
| JP (2) | JP6802791B2 (OSRAM) |
| KR (1) | KR102597989B1 (OSRAM) |
| CN (1) | CN107406506A (OSRAM) |
| AR (1) | AR102921A1 (OSRAM) |
| AU (2) | AU2015358615B2 (OSRAM) |
| BR (1) | BR112017011749A2 (OSRAM) |
| CA (1) | CA2969717A1 (OSRAM) |
| CL (1) | CL2017001382A1 (OSRAM) |
| DO (1) | DOP2017000150A (OSRAM) |
| EA (2) | EA202092609A1 (OSRAM) |
| EC (1) | ECSP17042921A (OSRAM) |
| HK (1) | HK1247221A1 (OSRAM) |
| IL (2) | IL307913A (OSRAM) |
| JO (1) | JO3748B1 (OSRAM) |
| MX (1) | MX2017007208A (OSRAM) |
| NI (1) | NI201700071A (OSRAM) |
| PE (1) | PE20171094A1 (OSRAM) |
| PH (1) | PH12017501042A1 (OSRAM) |
| SG (1) | SG11201704390PA (OSRAM) |
| TW (2) | TWI721959B (OSRAM) |
| UA (1) | UA123697C2 (OSRAM) |
| UY (1) | UY36419A (OSRAM) |
| WO (1) | WO2016089960A1 (OSRAM) |
| ZA (1) | ZA202307128B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| WO2019109095A1 (en) * | 2017-12-01 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders |
| CN113194990A (zh) * | 2018-07-11 | 2021-07-30 | 动量制药公司 | 与靶向CD38的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021002415A (es) | 2018-08-28 | 2021-09-21 | Vor Biopharma Inc | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| GB201916150D0 (en) * | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
| IL293840A (en) * | 2019-12-13 | 2022-08-01 | Janssen Pharmaceuticals Inc | Methods and devices for delivering liquid therapeutic agents in solid tumors |
| EP4169949A4 (en) * | 2020-06-23 | 2024-08-21 | Jiangsu Kanion Pharmaceutical Co., Ltd. | ANTI-CD38 ANTIBODY AND ITS USE |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| TW202235435A (zh) | 2021-01-14 | 2022-09-16 | 德商莫菲西斯公司 | 抗cd38抗體及其用途 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| JP7767722B2 (ja) | 2021-03-16 | 2025-11-12 | 東ソー株式会社 | ラミネート用延伸ポリエチレンフィルム |
| US20250145730A1 (en) * | 2021-12-16 | 2025-05-08 | Shanghai Bao Pharmaceuticals Co., Ltd. | Anti-immunoglobulin degrading enzyme-digested fc variant |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100206524B1 (ko) | 1990-07-13 | 1999-07-01 | 어니스트 엠. 해데드 | 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이 |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
| AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| JP4233608B2 (ja) | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
| WO1998016254A1 (en) | 1996-10-17 | 1998-04-23 | Immunomedics, Inc. | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system |
| WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
| WO1998050435A1 (en) | 1997-05-02 | 1998-11-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunotoxins, comprising an onc protein, directed against malignant cells |
| CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US6734203B2 (en) | 2000-02-15 | 2004-05-11 | Akira Matsuhisa | Fused imidazolium derivatives |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| WO2001097844A1 (en) | 2000-06-22 | 2001-12-27 | Idec Pharmaceuticals Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| AU1331802A (en) | 2000-10-17 | 2002-04-29 | Trudeau Inst Inc | Cd38 modulated chemotaxis |
| US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| US7550140B2 (en) | 2002-06-13 | 2009-06-23 | Crucell Holland B.V. | Antibody to the human OX40 receptor |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| WO2004078140A2 (en) | 2003-03-05 | 2004-09-16 | Halozyme, Inc. | SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF |
| EP1614686B1 (en) | 2003-04-15 | 2014-05-07 | Astellas Pharma Inc. | Bromide and its crystal |
| RS20050885A (sr) | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| JP4794301B2 (ja) | 2003-06-11 | 2011-10-19 | 中外製薬株式会社 | 抗体の製造方法 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2542840A1 (en) | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
| PL1684805T3 (pl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostics Inc | Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40 |
| ATE536376T1 (de) | 2003-12-23 | 2011-12-15 | Crucell Holland Bv | Humanes bindungsmolekül gegen cd1a |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CN103554260A (zh) | 2005-10-12 | 2014-02-05 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| AU2006329944A1 (en) | 2005-12-09 | 2007-07-05 | Seattle Genetics, Inc. | Methods of using CD40 binding agents |
| CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| HUE026693T2 (hu) * | 2006-08-02 | 2016-07-28 | Sunesis Pharmaceuticals Inc | (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil) -1,8-naftiridin-3-karbonsav és cytarabin (Ara-C) kombinált alkalmazása leukémia kezelésére |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
| MX2009010179A (es) | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| ES2667863T3 (es) | 2007-03-29 | 2018-05-14 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| WO2008121615A2 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Inc. | Antibody formulation |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| CA2733676A1 (en) * | 2007-08-10 | 2009-02-19 | British Columbia Cancer Agency Branch | Microrna compositions and methods for the treatment of myelogenous leukemia |
| US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| US20110002934A1 (en) | 2007-11-09 | 2011-01-06 | Novartis Ag | Uses of anti-cd40 antibodies |
| WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
| CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| US8013125B2 (en) | 2008-03-03 | 2011-09-06 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
| PT4269578T (pt) | 2008-03-06 | 2024-06-18 | Halozyme Inc | Produção em grande escala de hialuronidase solúvel |
| TWI532498B (zh) | 2008-03-17 | 2016-05-11 | 巴克斯特保健公司 | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| MX2010009647A (es) | 2008-03-25 | 2010-09-28 | Roche Glycart Ag | Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano. |
| EP2662090A1 (en) | 2008-04-14 | 2013-11-13 | Halozyme, Inc. | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| SI2982696T1 (sl) | 2008-11-07 | 2019-06-28 | Amgen Research (Munich) Gmbh | Zdravljenje akutne limfoblastne levkemije |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SMT202000092T1 (it) * | 2009-05-14 | 2020-05-08 | Ambit Biosciences Corp | Formulazione essiccata a spruzzo o liofilizzata di ac220 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2477603B1 (en) | 2009-09-17 | 2016-03-30 | Baxalta Incorporated | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| JP5898082B2 (ja) | 2009-10-07 | 2016-04-06 | マクロジェニクス，インコーポレーテッド | フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法 |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| JP5937523B2 (ja) | 2010-03-01 | 2016-06-22 | サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． | 濃縮されたタンパク質製剤およびその使用 |
| GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| US20130137134A1 (en) | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2580243B1 (en) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antibodies against human cd38 |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| BR112013006769B1 (pt) | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| US9358233B2 (en) * | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| CL2013001944A1 (es) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| DK2688887T3 (en) * | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
| WO2012136732A1 (en) | 2011-04-08 | 2012-10-11 | Ab Science | Treatment of multiple myeloma with masitinib |
| US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
| EP2747571A4 (en) | 2011-08-24 | 2015-05-27 | David Kerr | COMBINED COMBINED CHEMOTHERAPY |
| EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
| KR102096224B1 (ko) | 2011-10-28 | 2020-04-03 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 폴리펩티드 구축물 및 이의 용도 |
| WO2013083140A1 (en) | 2011-12-07 | 2013-06-13 | N.V. Nutricia | Beta-lactoglobulin peptides for treating cow's milk protein allergy |
| LT3130347T (lt) | 2011-12-30 | 2019-10-25 | Halozyme Inc | Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas |
| WO2013116307A1 (en) * | 2012-01-30 | 2013-08-08 | Mount Sinai School Of Medicine | Method for programming differentiated cells into hematopoietic stem cells |
| KR101730694B1 (ko) | 2012-03-07 | 2017-04-27 | 카딜라 핼쓰캐어 리미티드 | TNF-α 항체의 약제학적 제형 |
| JP6042527B2 (ja) | 2012-04-04 | 2016-12-14 | ハロザイム インコーポレイテッド | 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| PL2900232T3 (pl) | 2012-09-25 | 2018-05-30 | Morphosys Ag | Kombinacje i ich zastosowania |
| ES2621377T3 (es) | 2012-11-05 | 2017-07-03 | Morphosys Ag | Anticuerpo marcado radiactivamente y usos del mismo |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| EA031025B1 (ru) | 2012-12-21 | 2018-11-30 | Сиэтл Дженетикс, Инк. | Антитела против ntb-a и связанные с ними композиции и способы |
| WO2014142220A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | 抗腫瘍剤 |
| US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
| EP2992013B1 (en) | 2013-04-29 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
| CA2919513A1 (en) | 2013-07-15 | 2015-01-22 | Matthew J. Goldstein | Medical uses of cd38 agonists |
| JP2016536361A (ja) | 2013-11-06 | 2016-11-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 |
| EP3105317B1 (en) | 2014-02-14 | 2018-09-19 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10106620B2 (en) * | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| MA39070A1 (fr) | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| MA41555A (fr) | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| KR20180025888A (ko) | 2015-06-08 | 2018-03-09 | 제넨테크, 인크. | 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법 |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN107921050A (zh) | 2015-06-29 | 2018-04-17 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| US20230391884A1 (en) | 2016-06-28 | 2023-12-07 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| AU2019244478B2 (en) | 2018-03-28 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| US20190298827A1 (en) | 2018-04-03 | 2019-10-03 | Janssen Biotech, Inc. | Methods of Treating Multiple Myeloma |
| JOP20200292A1 (ar) | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
| BR112021007227A2 (pt) | 2018-10-17 | 2021-08-10 | Janssen Biotech, Inc. | método para fornecer administração subcutânea de anticorpos anti-cd38 |
| EP3880824B1 (en) | 2018-11-13 | 2024-07-24 | Janssen Biotech, Inc. | Control of trace metals during production of anti-cd38 antibodies |
| US20200268847A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Biotech, Inc. | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone |
| US20200308296A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
| US20200316197A1 (en) | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
| US20200308297A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses |
| WO2020194243A1 (en) | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone |
| US20200330593A1 (en) | 2019-03-28 | 2020-10-22 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone |
| US20200405854A1 (en) | 2019-04-19 | 2020-12-31 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| US20200397896A1 (en) | 2019-04-19 | 2020-12-24 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| US20200392242A1 (en) | 2019-04-19 | 2020-12-17 | Janssen Biotech, Inc. | Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses |
| WO2020243911A1 (zh) | 2019-06-04 | 2020-12-10 | 上海科技大学 | Nad+和/或nad+抑制剂和/或nad+激动剂的用途及其联合制剂 |
| US20220275101A1 (en) | 2021-02-09 | 2022-09-01 | Janssen Biotech, Inc. | Use of Approved Anti-CD38 Antibody Drug Product to Treat Light Chain Amyloidosis |
| US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
-
2015
- 2015-12-02 KR KR1020177017757A patent/KR102597989B1/ko active Active
- 2015-12-02 WO PCT/US2015/063371 patent/WO2016089960A1/en not_active Ceased
- 2015-12-02 TW TW104140257A patent/TWI721959B/zh active
- 2015-12-02 CN CN201580075548.5A patent/CN107406506A/zh active Pending
- 2015-12-02 IL IL307913A patent/IL307913A/en unknown
- 2015-12-02 EP EP15865128.1A patent/EP3227338A4/en active Pending
- 2015-12-02 US US14/956,890 patent/US10793630B2/en active Active
- 2015-12-02 BR BR112017011749A patent/BR112017011749A2/pt not_active Application Discontinuation
- 2015-12-02 SG SG11201704390PA patent/SG11201704390PA/en unknown
- 2015-12-02 JP JP2017529743A patent/JP6802791B2/ja active Active
- 2015-12-02 EA EA202092609A patent/EA202092609A1/ru unknown
- 2015-12-02 MX MX2017007208A patent/MX2017007208A/es unknown
- 2015-12-02 UA UAA201706786A patent/UA123697C2/uk unknown
- 2015-12-02 AU AU2015358615A patent/AU2015358615B2/en active Active
- 2015-12-02 HK HK18106919.5A patent/HK1247221A1/zh unknown
- 2015-12-02 CA CA2969717A patent/CA2969717A1/en active Pending
- 2015-12-02 PE PE2017000966A patent/PE20171094A1/es unknown
- 2015-12-02 TW TW110104368A patent/TWI775309B/zh active
- 2015-12-02 EA EA201791208A patent/EA037084B9/ru unknown
- 2015-12-03 JO JOP/2015/0298A patent/JO3748B1/ar active
- 2015-12-04 AR ARP150103977A patent/AR102921A1/es unknown
- 2015-12-04 UY UY0001036419A patent/UY36419A/es not_active Application Discontinuation
-
2017
- 2017-05-29 IL IL252568A patent/IL252568A0/en unknown
- 2017-05-30 CL CL2017001382A patent/CL2017001382A1/es unknown
- 2017-06-02 NI NI201700071A patent/NI201700071A/es unknown
- 2017-06-05 PH PH12017501042A patent/PH12017501042A1/en unknown
- 2017-06-22 DO DO2017000150A patent/DOP2017000150A/es unknown
- 2017-07-05 EC ECIEPI201742921A patent/ECSP17042921A/es unknown
-
2020
- 2020-08-27 US US17/005,039 patent/US12286474B2/en active Active
- 2020-11-25 JP JP2020195547A patent/JP2021042232A/ja active Pending
-
2021
- 2021-08-17 AU AU2021218021A patent/AU2021218021B2/en active Active
-
2023
- 2023-07-17 ZA ZA2023/07128A patent/ZA202307128B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA123697C2 (uk) | Спосіб лікування гострого мієлоїдного лейкозу шляхом застосування антитіла до cd38 | |
| US11021543B2 (en) | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 | |
| UA122961C2 (uk) | Спосіб лікування суб’єкта, який має рецидивуючий або рефрактерний гострий лімфобластний лейкоз | |
| KR102012113B1 (ko) | 항-pd-1 항체 및 그의 사용 방법 | |
| UA122395C2 (uk) | Антитіло проти tigit | |
| UA122212C2 (uk) | Вид комбінованої терапії з застосуванням антитіла до cd38 | |
| UA124799C2 (uk) | Спосіб пригнічення імунної відповіді з використанням антитіла, що специфічно зв’язує cd38 | |
| UA125115C2 (uk) | Спосіб лікування суб'єкта, який має множинну мієлому (мм) | |
| UA118013C2 (uk) | Комбінована терапія з використанням антитіла до клаудину 18.2 для лікування раку | |
| US20220396632A1 (en) | Anti-psgl-1 compositions and methods for modulating myeloid cell infalmmatory phenotypes and uses thereof | |
| CA3142433A1 (en) | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| WO2021243169A1 (en) | Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| EP3990015A1 (en) | Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| US20220363752A1 (en) | Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| EA050043B1 (ru) | Антитела к cd38 для лечения острого миелолейкоза | |
| UA112157C2 (uk) | МОНОКЛОНАЛЬНЕ АНТИТІЛО ДО c-Mеt | |
| HK1244492B (zh) | 抗pd-1抗体及其使用方法 |